01244.HK
3D Medicines Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 2.46
−2.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 806.1M | 356.1M | 445.6M | 634.9M | 567.4M |
| Cost of Revenue | 115.7M | 57.1M | 73.9M | 110.9M | 42.2M |
| Gross Profit | 690.3M | 299.0M | 371.7M | 524.0M | 525.2M |
| Operating Expenses | |||||
| R&D Expense | 314.9M | 156.1M | 180.7M | 425.5M | 350.9M |
| SG&A Expense | 563.3M | 255.5M | 314.4M | 595.9M | 500.5M |
| General & Admin Expense | 105.2M | 70.4M | 78.3M | 217.1M | 142.8M |
| Selling & Marketing Expense | 311.1M | 185.2M | 235.9M | 378.8M | 357.7M |
| Other Expenses | 5.5M | — | — | (123.0K) | (4.8M) |
| Total Operating Expenses | 883.8M | 411.6M | 495.2M | 1.0B | 846.5M |
| Cost and Expenses | 999.5M | 468.7M | 569.1M | 1.1B | 953.6M |
| Operating Income (EBIT) | (193.5M) | (112.7M) | (123.4M) | (497.2M) | (386.2M) |
| Non-Operating | |||||
| Interest Income | 34.4M | 20.3M | 10.9M | 6.5M | 7.2M |
| Interest Expense | 4.3M | 5.1M | 9.5M | 7.8M | 3.1M |
| Net Interest Income | 30.0M | 15.2M | 1.4M | (1.2M) | 4.1M |
| Other Non-Op Income/Expense | (165.4M) | (72.3M) | (75.9M) | (65.2M) | (665.9M) |
| Non-Operating Income (excl Interest) | 140.3M | 93.7M | 111.4M | 57.4M | 727.6M |
| EBT (Pre-Tax Income) | (358.8M) | (184.9M) | (199.4M) | (562.5M) | (1.1B) |
| Income Tax Expense | 27.5K | (53.6K) | — | 55.0K | — |
| Bottom Line | |||||
| Net Income | (342.0M) | (177.5M) | (182.7M) | (524.7M) | (1.0B) |
| Earnings from Cont. Ops | (358.9M) | (184.9M) | (199.4M) | (562.5M) | (1.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (342.0M) | (177.5M) | (182.7M) | (524.7M) | (1.0B) |
| Per Share | |||||
| Basic EPS | (HK$1.39) | (HK$0.72) | (HK$0.75) | (HK$2.30) | (HK$22.52) |
| Diluted EPS | (HK$1.39) | (HK$0.72) | (HK$0.75) | (HK$2.30) | (HK$22.52) |
| Revenue Per Share | HK$3.28 | HK$1.45 | HK$1.82 | HK$2.78 | HK$12.47 |
| Shares | |||||
| Basic Shares Outstanding | 245.9M | 245.5M | 245.0M | 228.5M | 45.5M |
| Diluted Shares Outstanding | 245.9M | 245.5M | 245.0M | 228.5M | 45.5M |
| Profitability Metrics | |||||
| EBITDA | (319.3M) | (197.4M) | (227.0M) | (529.2M) | (1.0B) |
| D&A | 14.4M | 8.9M | 7.9M | 25.5M | 21.6M |
| EBIT | (333.8M) | (206.3M) | (234.8M) | (554.7M) | (1.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026